{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-23-000382","form_type":"8-K","ticker":"LIPO","cik":"0001347242","company_name":"LIPELLA PHARMACEUTICALS INC.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.522822+00:00","generated_at":"2026-06-17T06:50:32.820061+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lipella completes Phase 2a trial of LP-10 for hemorrhagic cystitis; reports $5.1M cash, IPO completed","bullets":["Completed Phase 2a trial of LP-10 for hemorrhagic cystitis; top-line results showed no serious adverse events and reduced symptoms.","Year-end cash $5.1M, provides operating runway into 2024.","Appointed Douglas Johnston as CFO in November 2022.","Completed IPO and Nasdaq listing in December 2022.","Created Oral Health Scientific Advisory Board for LP-310; results to be presented at AUA meeting April 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-23-000382","json":"https://secwatch.observer/filing/0001753926-23-000382.json","markdown":"https://secwatch.observer/filing/0001753926-23-000382.md","text":"https://secwatch.observer/filing/0001753926-23-000382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347242/000175392623000382/0001753926-23-000382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347242/000175392623000382/g083471_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:50:32.820061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"97e74fc86366fde381451e2893b3a87a811eb574","claim":"LIPELLA PHARMACEUTICALS INC. reported financial results for the fiscal year ended December 31, 2022.","evidence_excerpt":"today provided a business update and reported financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347242/000175392623000382/0001753926-23-000382-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}